NCT04856124View on ClinicalTrials.gov

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

December 15, 2020

Study Completion Date

March 1, 2021

Conditions
Treatment Resistant Depression
Interventions
DRUG

Intranasal esketamine

Subjects with a clinically meaningful response to IV racemic ketamine were switched to IN esketamine

Trial Locations (1)

30060

PsychAtlanta, Marietta

All Listed Sponsors
lead

Psych Atlanta

OTHER

NCT04856124 - Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine | Biotech Hunter | Biotech Hunter